^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EMT gene signature

    3ms
    A partial epithelial-mesenchymal transition signature for highly aggressive colorectal cancer cells that survive under nutrient restriction. (PubMed, J Pathol)
    Both gene signature and E-cadherin alterations could be reversed by the proteasomal inhibitor MG132..
    Journal
    |
    EGFR (Epidermal growth factor receptor) • CDH1 (Cadherin 1) • SOX10 (SRY-Box 10) • SERPINE1 (Serpin Family E Member 1) • ITK (IL2 Inducible T Cell Kinase)
    |
    EGFR expression • EMT gene signature
    |
    MG132
    4ms
    Comprehensive analyses and experimental verification of NETs and an EMT gene signature for prognostic prediction, immunotherapy, and chemotherapy in pancreatic adenocarcinoma. (PubMed, Environ Toxicol)
    Transwell assays and western blotting showed that cell invasion and EMT induction were significantly reduced after DCBLD2 knockdown. Collectively, we constructed a prognosis model based on a NET and EMT gene signature, providing a valuable perspective for the prognostic evaluation and management of PAAD patient.
    Journal • Gene Signature • IO biomarker
    |
    ITK (IL2 Inducible T Cell Kinase)
    |
    EMT gene signature
    5ms
    Attenuating epithelial-to-mesenchymal transition in cancer through angiopoietin-like 4 inhibition in a 3D tumor microenvironment model. (PubMed, Adv Healthc Mater)
    Suppression of Angptl4 using antisense oligonucleotides or anti-cAngptl4 antibodies led to a dose-dependent abolishment of EMT-mediated chemoresistance and tumor self-organization in 3D, ultimately resulting in diminished metastatic potential and stunted growth of tumor xenografts. Our unique programmable 3D cancer cultures simulated stiffness levels in the tumor microenvironment and unveiled Angptl4 as a promising therapeutic target to inhibit EMT and impede cancer progression.
    Journal
    |
    ITK (IL2 Inducible T Cell Kinase) • ANGPTL4 (Angiopoietin Like 4)
    |
    EMT gene signature
    8ms
    Systematic establishment and verification of an epithelial-mesenchymal transition gene signature for predicting prognosis of oral squamous cell carcinoma. (PubMed, Front Genet)
    After validation, AREG, COL5A3, DKK1, GAS1, GPX7 and PLOD2 were distinctly upregulated and SFRP1 was downregulated in OSCC than normal tissues. Our data identified and verified a robust EMT gene signature in OSCC, which provided a novel clinical tool for predicting prognosis and several targets against OSCC therapy.
    Journal • Gene Signature
    |
    DKK1 (dickkopf WNT signaling pathway inhibitor 1) • GAS1 (Growth Arrest Specific 1) • ITK (IL2 Inducible T Cell Kinase) • PLOD2 (procollagen-lysine,2-oxoglutarate 5-dioxygenase 2) • SFRP1 (Secreted frizzled related protein 1) • GPX7 (Glutathione Peroxidase 7)
    |
    EMT gene signature
    9ms
    Epithelial-to-Mesenchymal Transition Gene Signature in Circulating Melanoma Cells: Biological and Clinical Relevance. (PubMed, Int J Mol Sci)
    In conclusion, We established a reliable qRT-PCR protocol with high sensitivity and specificity to characterize the gene expression of isolated CMCs. To our knowledge, this is the first evidence demonstrating the impact of immune or targeted therapies on EMT hallmark gene expressions in CMCs from advanced melanoma patients.
    Journal • Gene Signature
    |
    ITK (IL2 Inducible T Cell Kinase)
    |
    EMT gene signature
    10ms
    Prognostic significance of EMT gene signature in mesothelioma (IMIG 2023)
    No abstract available
    Gene Signature
    |
    ITK (IL2 Inducible T Cell Kinase)
    |
    EMT gene signature
    11ms
    Epithelial-to-mesenchymal transition is a major contributor to intratumor heterogeneity in lymph node breast cancer metastasis (EACR 2023)
    Further, the presence of cancer cell clusters located between the epithelial and mesenchymal cluster might point towards cells in an intermediated hybrid state. ConclusionScRNA-seq can be utilized to visualize intratumor heterogeneity and to identify the underlying molecular mechanism affected by metastasis to the lymph nodes in breast cancer.
    ITK (IL2 Inducible T Cell Kinase)
    |
    EMT gene signature
    1year
    Prognostic Value of EMT Gene Signature in Malignant Mesothelioma. (PubMed, Int J Mol Sci)
    In conclusion, we observed that the expression of a panel of MESO EMT genes was associated with hypermethylation of epigenetic genes and loss of expression of CDKN2A and CDKN2B. Expression of MESO EMT genes was associated with downregulation of the type I and type II IFN response, loss of cytotoxicity and NK cell activity, and upregulation of specific immune checkpoints, as well as upregulation of the TGF-β1/TGFBR1 pathway.
    Journal • Gene Signature • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • PD-L2 (Programmed Cell Death 1 Ligand 2) • VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • SERPINH1 (Serpin family H member 1) • ACTA2 (Actin Alpha 2 Smooth Muscle) • TGFB1 (Transforming Growth Factor Beta 1) • IFNA1 (Interferon Alpha 1) • ITK (IL2 Inducible T Cell Kinase) • KIR2DL3 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Long Cytoplasmic Tail 3) • COL5A2 (Collagen Type V Alpha 2 Chain) • KIR2DL1 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Long Cytoplasmic Tail 1) • LGALS9 (Galectin 9) • TGFBR1 (Transforming Growth Factor Beta Receptor 1)
    |
    EMT gene signature • CDKN2B expression
    over1year
    A transcriptomic map of EGFR-induced epithelial-to-mesenchymal transition identifies prognostic and therapeutic targets for head and neck cancer. (PubMed, Mol Cancer)
    EGFR-mediated EMT conveyed through MAPK activation contributes to HNSCC progression upon induction of migration and invasion. A 5-gene risk score based on a novel EGFR-mediated EMT signature prognosticated survival of HNSCC patients and determined ITGB4 as potential therapeutic and predictive target in patients with strong EGFR-mediated EMT.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • FADD (Fas associated via death domain) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • ITK (IL2 Inducible T Cell Kinase) • DDIT4 (DNA Damage Inducible Transcript 4)
    |
    EMT gene signature
    |
    Erbitux (cetuximab)
    over1year
    Epithelial-Mesenchymal Transition Gene Signature Is Associated with Neoadjuvant Chemoradiotherapy Resistance and Prognosis of Esophageal Squamous Cell Carcinoma. (PubMed, Dis Markers)
    The identified genes have the potential to function as molecular biomarkers for predicting ESCC patients' resistance to neo-CRT. This research may aid in the elucidation of the molecular processes driving resistance and the identification of targets for improving the prognosis for ESCC.
    Journal • Gene Signature
    |
    ITK (IL2 Inducible T Cell Kinase) • KCNN4 (Potassium Calcium-Activated Channel Subfamily N Member 4)
    |
    EMT gene signature
    over1year
    A novel epithelial-mesenchymal transition gene signature for the immune status and prognosis of hepatocellular carcinoma. (PubMed, Hepatol Int)
    Our novel prognostic signature model has a vital impact on immune status and prognosis, significantly helping the decision-making related to the diagnosis and treatment of patients with HCC.
    Journal • Gene Signature • IO biomarker
    |
    GADD45B (Growth Arrest And DNA Damage Inducible Beta)
    |
    EMT gene signature
    almost2years
    Definition of an EMT-related gene signature to track circulating metastasis initiating cells in lung cancer (EACR 2022)
    Conclusion Our analysis with dPCR confirms the efficacy of a refined EMT-gene signature to specifically detect MICs in processed PBMC samples. Furthermore silencing experiments evidence that selected genes could impact MICs maintenance and may represent novel MIC’s specific targets.
    Gene Signature
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4) • ITK (IL2 Inducible T Cell Kinase) • PRRX1 (Paired Related Homeobox 1) • MMP3 (Matrix metallopeptidase 3)
    |
    CDH1 expression • EMT gene signature
    almost2years
    TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling. (PubMed, Mol Cancer Res)
    Last, we show that genetic and pharmacological inhibition of SMURF1 inhibits the migration of aggressive mesenchymal bladder cancer cells. Implications: Our findings identify E3 ubiquitin ligase TRAF4 as a potential therapeutic target or biomarker for bladder cancer progression.
    Journal
    |
    AFF1 (AF4/FMR2 Family Member 1) • ITK (IL2 Inducible T Cell Kinase) • SMURF1 (SMAD Specific E3 Ubiquitin Protein Ligase 1)
    |
    EMT gene signature
    almost2years
    Cytokeratins 5 and 17 maintain an aggressive epithelial state in basal-like breast cancer. (PubMed, Mol Cancer Res)
    Loss of CK5 or CK17 moderately reduced the IC50 dose of doxorubicin in vitro and led to increased doxorubicin efficacy in vivo. Single-cell RNA-sequencing of BLBC patient-derived xenografts identified heterogeneous populations of CK5/CK17, vimentin, and dual basal CK/vimentin positive cells that fell on an EMT spectrum of epithelial, mesenchymal, and intermediate, respectively, while knockdown of CK5 transitioned cells towards a more mesenchymal score. Implications: This study supports that basal CKs 5 and 17 contribute to the adverse behavior of BLBC cells and could be an untapped source of therapeutic vulnerability for this aggressive disease.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • CDH1 (Cadherin 1) • VIM (Vimentin)
    |
    HER-2 negative • CDH1 expression • EMT gene signature • VIM expression
    |
    doxorubicin hydrochloride
    2years
    Epithelial-Mesenchymal Transition-Based Gene Signature and Distinct Molecular Subtypes for Predicting Clinical Outcomes in Breast Cancer. (PubMed, Int J Gen Med)
    We characterized five breast cancer subtypes with distinct clinical outcomes and immune status. The study developed an 11-EMT gene-signature as an independent prognostic factor for predicting clinical outcomes of breast cancer.
    Clinical data • Journal • Gene Signature
    |
    ITK (IL2 Inducible T Cell Kinase)
    |
    EMT gene signature
    2years
    Inhibition of novel kinase MAP3K19 reverses EMT and kills triple negative breast cancer cell lines (AACR 2022)
    Treatment with AT-9283, a more specific MAP3K19 inhibitor, resulted in cellular death and reversal in EMT gene signature by qPCR. Future directions for this project involve genetic knock-down and overexpression of MAP3K19 to evaluate its roles in biology and its signaling mechanisms.
    Preclinical
    |
    HER-2 (Human epidermal growth factor receptor 2) • ITK (IL2 Inducible T Cell Kinase)
    |
    HER-2 amplification • EMT gene signature
    |
    AT9283
    2years
    A panel of emerging EMT genes identified in malignant mesothelioma. (PubMed, Sci Rep)
    The expression of these genes was confirmed in our patients and human cell lines. Our findings suggest that these genes may be novel targets for therapeutics and prognosis in MESO and other types of cancers.
    Journal
    |
    ACTA2 (Actin Alpha 2 Smooth Muscle) • ITK (IL2 Inducible T Cell Kinase) • COL5A2 (Collagen Type V Alpha 2 Chain)
    |
    EMT gene signature
    2years
    Deep Learning-Based Classification of Epithelial-Mesenchymal Transition for Predicting Response to Therapy in Clear Cell Renal Cell Carcinoma. (PubMed, Front Oncol)
    Deep learning convolutional neural networks could be an extremely useful tool for predicting the EMT molecular classification of ccRCC tissue. The underlying multiomics information can be crucial in applying the appropriate and tailored targeted therapy to the patient.
    Journal • IO biomarker
    |
    ITK (IL2 Inducible T Cell Kinase)
    |
    EMT gene signature
    2years
    A Prognostic Risk Score Based on Hypoxia-, Immunity-, and Epithelialto-Mesenchymal Transition-Related Genes for the Prognosis and Immunotherapy Response of Lung Adenocarcinoma. (PubMed, Front Cell Dev Biol)
    Evaluation of the GSE126044 and IMvigor210 cohorts indicated that PD-1/PD-LI inhibitor treatment may be indicated in patients with low risk scores, while anti-cancer therapy with various drugs may be indicated in patients with high risk scores. Our novel risk model developed based on hypoxia, immune, and EMT gene signatures can aid in predicting clinical prognosis and guiding treatment in patients with LUAD.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    ITK (IL2 Inducible T Cell Kinase)
    |
    EMT gene signature
    2years
    TGF-β-mediated epithelial-mesenchymal transition and tumor-promoting effects in CMT64 cells are reflected in the transcriptomic signature of human lung adenocarcinoma. (PubMed, Sci Rep)
    Furthermore, TGF-β-induced gene enrichment was related to poor prognosis, underscoring the tumor-promoting role of TGF-β signaling in lung adenocarcinoma. Our cellular and syngeneic transplantation model would provide a simple and useful experimental tool to study the significance of TGF-β signaling and EMT.
    Journal
    |
    CD44 (CD44 Molecule) • TGFB1 (Transforming Growth Factor Beta 1) • ITK (IL2 Inducible T Cell Kinase) • TJP1 (Tight Junction Protein 1)
    |
    EMT gene signature
    over2years
    Identification of AR driven tumors within TNBC using a novel gene signature (SABCS 2021)
    Conclusion Identification of AR driven tumors within TNBC has both prognostic and predictive utility. Methods using limited number of AR regulated genes could be easily applied to larger BC cohorts to identify TNBC tumours driven by AR signalling and may respond well to anti-androgen therapies.
    Gene Signature
    |
    ER (Estrogen receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • FOXA1 (Forkhead Box A1) • GATA3 (GATA binding protein 3) • ITK (IL2 Inducible T Cell Kinase) • SOCS2 (Suppressor Of Cytokine Signaling 2) • TFF1 (Trefoil Factor 1)
    |
    TP53 mutation • PIK3CA mutation • AR positive • AR expression • ER overexpression • EMT gene signature
    |
    TNBCType-IM assay
    over2years
    BGBC004: A Study of BGB324(Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=40, Completed, BerGenBio ASA | Recruiting --> Completed | N=66 --> 40 | Trial completion date: Jul 2018 --> Aug 2021 | Trial primary completion date: Dec 2017 --> Aug 2021
    Clinical • Trial completion • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • GAS6 (Growth arrest specific 6)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EMT gene signature • EGFR rearrangement
    |
    Tagrisso (osimertinib) • erlotinib • bemcentinib (BGB324)
    over2years
    Eosinophilic features in clear cell renal cell carcinoma correlate with outcomes of immune checkpoint and angiogenesis blockade. (PubMed, J Immunother Cancer)
    The histological phenotype based on the eosinophilic features, which are linked to major immunological mechanisms of ccRCC, was significantly correlated with therapeutic efficacy.
    Journal • IO biomarker
    |
    PBRM1 (Polybromo 1)
    |
    EMT gene signature
    almost3years
    Identification of a Novel Epithelial-Mesenchymal Transition Gene Signature Predicting Survival in Patients With HNSCC. (PubMed, Pathol Oncol Res)
    The prognostic ability of the gene signature was further validated in an independent cohort from the Gene Expression Omnibus (GEO) database. In conclusion, we identified a four-EMT-based gene signature which provides the potentiality to serve as novel independent biomarkers for predicting survival in HNSCC patients, as well as a new possibility for individualized treatment of HNSCC.
    Clinical • Journal • Gene Signature
    |
    PLOD2 (procollagen-lysine,2-oxoglutarate 5-dioxygenase 2)
    |
    EMT gene signature
    almost3years
    Extracellular domain shedding of the ALK receptor mediates neuroblastoma cell migration. (PubMed, Cell Rep)
    We further show that cleavage is mediated by matrix metalloproteinase 9, whose genetic and pharmacologic inactivation inhibits cleavage and decreases NB cell migration. Together, our results indicate a pivotal role for WT ALK ECD cleavage in NB pathogenesis, which may be harnessed for therapeutic benefit.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • MMP9 (Matrix metallopeptidase 9) • ITK (IL2 Inducible T Cell Kinase)
    |
    EMT gene signature
    almost3years
    Epithelial-mesenchymal transition induced by SARS-CoV-2 required transcriptional upregulation of Snail. (PubMed, Am J Cancer Res)
    Suppression of Snail expression in these cells abrogates S protein-induced invasion, migration, stemness, and lung metastasis, suggesting that Snail is required for SARS-CoV-2-mediated aggressive phenotype in cancer. This study reveals an important oncogenic role of SARS-CoV-2 in triggering breast cancer metastasis through Snail upregulation.
    Journal
    |
    TMPRSS2 (Transmembrane serine protease 2)
    |
    EMT gene signature
    almost3years
    Epithelial-Mesenchymal Transition Gene Signature Related to Prognostic in Colon Adenocarcinoma. (PubMed, J Pers Med)
    A qRT-PCR validation step was conducted in a COAD patient cohort comprising of 29 tumor tissues and 29 normal adjacent tissues, endorsing the expression level for BMP5, as well as for two of the miRNAs targeting key EMT related genes, revealing upregulation of miR-27a-5p and miR-146a-5p. The EMT signature can be used to develop a panel of biomarkers for recurrence prediction in COAD patients, which may contribute to the improvement of risk stratification for the patients.
    Journal • Gene Signature
    |
    MIR27A (MicroRNA 27a) • SFRP1 (Secreted frizzled related protein 1)
    |
    EMT gene signature